Hi Bripoz,There is an interesting question about phase 3...

Hi Bripoz,

There is an interesting question about phase 3 collaboration. If a big pharma partnered development of Cavatak for melanoma, would they automatically acquire the rights to use it intravenously, ie the uk STORM trial for lung, bladder, and prostrate cancers? I guess that would be the subject of negotiation but it certainly gives Viralytics more leverage.

There's also the possible synergy between Cavatak and chemotherapy agents identified in preclinical trials which again increases leverage and which must make it attractive to a chemo agent manufacturer.

You've mentioned that Amgen got their fingers burnt by their acquisition of t-vec, all the announcements I've seen suggest their phase 3 trial is going well, can you clarify your source for this? This is an important point for VLA as it provides validation of the virotherapy approach.

Regards